Bristol-Myers Squibb discusses Sprycel potential

Bristol-Myers Squibb’s preliminary results from trials of Sprycel (dasatinib) to treat a number of life-threatening tumour types are promising, it has stated.

The medication is currently indicated for use in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia or intolerance to prior therapy for chronic myeloid leukaemia.

Interim data from two studies of the drug showing it could be able to work for castrate-resistant prostate cancer (CRPC) will be presented at the American Society for Clinical Oncology annual meeting.

Dr David Shapiro, vice-president of the Sprycel development team, noted a comprehensive approach is needed to target the tumour and bone microenvironment in CRPC patients.

“Sprycel is the most clinically advanced SRC inhibitor with demonstrated efficacy and safety in patients with solid tumours,” he said.

This week, Bristol-Myers Squibb presented at the Bank of America and Merrill Lynch Health Care Conference.

President and chief operating officer of the company Lamberto Andreotti discussed the business’ earnings guidance.

The presentation was broadcast live on the firm’s website and an archived edition of the talk is available online.